Zydus Launches 'Zyrifa' Biosimilar for Cancer Bone Complications

• Zydus Lifesciences launched 'Zyrifa', a Denosumab biosimilar (120 mg SC).
• 'Zyrifa' is designed to treat bone complications (SREs) in patients with advanced cancers, including bone metastases.
• The monoclonal antibody helps prevent bone complications in various cancer types like breast, prostate, lung, and multiple myeloma.
• Priced at ₹12,495, Zydus aims to improve access and affordability for cancer patients needing critical care.

Why It Matters: Zyrifa provides affordable treatment for cancer patients' bone complications.